Regulatory Update — Week of July 15, 2024

This week, the FDA published final guidance on drugs for treatment of partial onset seizures, combination product user fees, radiolabeled mass balance study clinical pharmacology considerations. Draft guidance was issued on pediatric inflammatory bowel disease. The agency also announced interactive site tours of biotechnology manufacturing facilities developing cellular and gene therapies.
Source: Drug Industry Daily